- Home
- » Tags
- » Etirinotecan pegol
Top View
- Etirinotecan Pegol for Metastatic Breast Cancer - Second Or Subsequent Line
- Systemic Therapy of Central Nervous System Metastases of Breast Cancer
- Investigational Chemotherapy and Novel Pharmacokinetics for the Treatment of Cancers of the CNS
- Orphan Drug Designation List
- Dallas for Its Newest Hope Lodge
- American Society of Clinical Oncology Annual Meeting
- Anal Cancer in the Last 12 Months
- Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) As a Second-Line Treatment in Patients with Relapsed Or Refractory Small Cell Lung Cancer (SCLC)
- Etirinotecan Pegol Administration Is Associated with Lower Incidences of Neutropenia Compared to Irinotecan Administration
- Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin®-Refractory High- Grade Glioma Presented at 50Th ASCO Meeting
- ASCO 2012 TIP Poster
- THERAPY CODES 4-Factor Concentrate F014 5A2A F017
- What About « Triple Negative » Breast Cancer
- A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors
- WO 2016/123581 Al 4 August 2016 (04.08.2016) P O P C T
- 安列庫帕凍晶靜脈注射劑60 毫克(ALIQOPA 60 Mg, Powder For
- BPCA Pediatric Oncology Core Working Group Conference Call
- (12) Patent Application Publication (10) Pub. No.: US 2016/0221987 A1 Decrescenzo Et Al
- Oncology Drugs in the Pipeline
- Phase III Study of Etirinotecan Pegol Versus Treatment of Physician's
- 1078-0432.CCR-12-1201.Full.Pdf
- Oncology Drugs in the Pipeline
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Chemotherapy Options for Patients Suffering from Heavily Pretreated Metastatic Breast Cancer
- Camptothecin-Discovery, Clinical Perspectives and Biotechnology
- Consolidation Therapy for HER2 Negative (0–2+) Metastatic Breast Cancer
- Chemotherapy Options Beyond the First Line in HER-Negative Metastatic Breast Cancer
- February 19, 2016 NCT02312622 Coordinating Center Stanford Cancer Institute 875 Blake Wilbur Drive Stanford, CA 94305
- Oncology Drugs in the Pipeline
- Draft Scope (Pre-Referral)
- (NKTR-102) in Bevacizumab-Resistant High Grade Glioma
- Camptothecin Conjugates and Analogs Topotecan
- Antineoplastic Drugs
- Onzeald, INN-Etirinotecan Pegol
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Irinotecan As a Palliative Therapy for Metastatic Breast Cancer Patients with Previous Chemotherapy
- Roswell Park Cancer Institute Study Number: I 225612
- Working Group Report, July 2016